ALNY - Alnylam is lower after releasing topline data for lumasiran from kidney disease trial

Alnylam Pharmaceuticals (NASDAQ:ALNY) has lost ~1.4% in the pre-market after the company announced topline results from a Phase 3 study which was designed to evaluate lumasiran in patients with primary hyperoxaluria type 1 (PH1) associated with a decline in renal function. The ILLUMINATE-C is an open-label multinational study involving six patients in cohort A with advanced PH1 who do not yet require dialysis and 15 patients in cohort B who are dependent on hemodialysis. The primary efficacy endpoint for Cohort A is the percent change in plasma oxalate from baseline to month six and for cohort B it is the percent change in pre-dialysis plasma oxalate from baseline over six months. After six months, there was a “substantial reduction in plasma oxalate from baseline in patients (N=21), with advanced disease including those on hemodialysis” Alnylam said in the statement. However, there were two discontinuations during the extension period of the trial due to

For further details see:

Alnylam is lower after releasing topline data for lumasiran from kidney disease trial